Company news

Compass Therapeutics, Inc. news in 2026

Compass Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Compass Therapeutics to Participate in Upcoming November Investor Events

November 2, 2026

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

October 24, 2026

Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 14, 2026

Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback

September 22, 2026

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

August 6, 2026

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

July 17, 2026

Compass Therapeutics to Participate in Upcoming June Investor Events

May 28, 2026

Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting

May 21, 2026

Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update

May 4, 2026

Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

April 27, 2026

Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer

April 24, 2026

Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update

March 4, 2026

Compass Therapeutics Provides Corporate Update

January 5, 2026

Compass Therapeutics Announces Key Leadership Appointments

January 4, 2026

Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 4, 2026

Decks in 2026